GlassScriptPhysician profile
Thomas Pendergast
NPI 1407849094
$8,246.42
in general payments reported to CMS, 2019-2025
29 companies · $854 in 2025
The $854 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $98.48 · 2021: $88.11 · 2022: $2,358 · 2023: $3,580 · 2024: $470 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645 · Travel and Lodging: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.16 |
| Travel and Lodging | $2,258.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $3,058.58 | 2023-2025 | Evoke Scs, Evoke |
| Relievant Medsystems, INC. | $1,418.54 | 2022-2023 | Intracept |
| Abbott Laboratories | $781.28 | 2019-2025 | Proclaim, Eterna |
| Vertos Medical, INC. | $711.59 | 2019-2024 | Mild Device Kit |
| Medtronic, INC. | $588.59 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Boston Scientific Corporation | $410.65 | 2019-2025 | General - Pain Management |
| Mml US, INC. | $388.82 | 2022-2025 | Reactiv8 |
| Medtronic USA, INC. | $154.59 | 2019 | |
| Alkermes, INC. | $100.35 | 2022-2024 | Aristada, Lybalvi |
| Lilly USA, LLC | $72.19 | 2023-2024 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.27 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $53.33 | 2023 | Rexulti, Abilify Maintena |
| Abbvie INC. | $46.44 | 2022-2024 | |
| Radius Health, INC. | $45.46 | 2023 | Tymlos |
| Amgen INC. | $42.59 | 2022-2023 | Prolia, Evenity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $40.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $33.24 | 2023-2024 | Strensiq |
| Lundbeck LLC | $31.06 | 2022-2024 | Rexulti |
| Pacira Pharmaceuticals Incorporated | $26.21 | 2025 | Exparel |
| Vertex Pharmaceuticals Incorporated | $22.67 | 2025 | |
| Averitas Pharma INC. | $22.13 | 2023 | Qutenza |
| Novo Nordisk INC | $22.07 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $19.73 | 2023 | Quviviq |
| Si-Bone, INC. | $18.51 | 2021 | |
| Painteq LLC | $18.26 | 2023 | Painteq |
| Neurocrine Biosciences, INC. | $17.10 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $14.70 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $14.53 | 2025 | Bridion |
| Azurity Pharmaceuticals, INC. | $14.03 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pendergast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.